Pharmaceutical combination of Anti-her3 antibody-drug conjugate and Anti-her2 antibody and use thereof

TW202641591APending Publication Date: 2026-10-16DUALITY BIOLOGICS (SUZHOU) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114152002
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-03-07
Filing Date
2025-12-30
Publication Date
2026-10-16

Smart Images

  • Figure TWG2TA001080838_001
    Figure TWG2TA001080838_001
  • Figure TWG2TA001080838_002
    Figure TWG2TA001080838_002
  • Figure TWG2TA001080838_003
    Figure TWG2TA001080838_003
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical combination of an anti-HER3 antibody-drug conjugate and an anti-HER2 antibody and a use of the pharmaceutical combination for the treatment of cancer. The pharmaceutical combination of the present invention is safe and has enhanced anti-tumor effects relative to single-drug administration. The pharmaceutical combination of the present invention exhibits a synergistic and potent tumor inhibitory effect. The present invention also relates to a kit of parts comprising the pharmaceutical combination.
Need to check novelty before this filing date? Find Prior Art